Abstract
Researchers in Canada previously demonstrated that patients who are taking both trimethoprim-sulfamethoxazole (TMP/SMX) and spironolactone are at excess risk for being hospitalized with hyperkalemia (NEJM JW Gen Med Nov 1 2011 and BMJ 2011; 343 : d5228). Now, the same team has performed a population-based case-control study in Ontario to determine whether this interaction might confer risk for sudden death, …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
